These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21196532)

  • 1. Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells.
    Cao A; Wu M; Li H; Liu J
    J Lipid Res; 2011 Mar; 52(3):518-30. PubMed ID: 21196532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
    Yan H; Ma YL; Gui YZ; Wang SM; Wang XB; Gao F; Wang YP
    Acta Pharmacol Sin; 2014 Aug; 35(8):994-1004. PubMed ID: 25042549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
    Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
    J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
    Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters.
    Wu M; Dong B; Cao A; Li H; Liu J
    Atherosclerosis; 2012 Oct; 224(2):401-10. PubMed ID: 22954675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway.
    Dong B; Li H; Singh AB; Cao A; Liu J
    J Biol Chem; 2015 Feb; 290(7):4047-58. PubMed ID: 25540198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
    Dong B; Wu M; Cao A; Li H; Liu J
    Int J Mol Med; 2011 Jan; 27(1):103-10. PubMed ID: 21069265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional activation of hepatic ACSL3 and ACSL5 by oncostatin m reduces hypertriglyceridemia through enhanced beta-oxidation.
    Zhou Y; Abidi P; Kim A; Chen W; Huang TT; Kraemer FB; Liu J
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2198-205. PubMed ID: 17761945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.
    Dong B; Wu M; Li H; Kraemer FB; Adeli K; Seidah NG; Park SW; Liu J
    J Lipid Res; 2010 Jun; 51(6):1486-95. PubMed ID: 20048381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
    Gupta N; Fisker N; Asselin MC; Lindholm M; Rosenbohm C; Ørum H; Elmén J; Seidah NG; Straarup EM
    PLoS One; 2010 May; 5(5):e10682. PubMed ID: 20498851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
    Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
    J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.
    Shende VR; Wu M; Singh AB; Dong B; Kan CF; Liu J
    J Lipid Res; 2015 Apr; 56(4):801-9. PubMed ID: 25652089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.
    Dong B; Singh AB; Azhar S; Seidah NG; Liu J
    Atherosclerosis; 2015 Apr; 239(2):364-74. PubMed ID: 25682035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
    Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
    J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling pathways implicated in oncostatin M-induced aggrecanase-1 and matrix metalloproteinase-13 expression in human articular chondrocytes.
    El Mabrouk M; Sylvester J; Zafarullah M
    Biochim Biophys Acta; 2007 Mar; 1773(3):309-20. PubMed ID: 17208315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice.
    Ai D; Chen C; Han S; Ganda A; Murphy AJ; Haeusler R; Thorp E; Accili D; Horton JD; Tall AR
    J Clin Invest; 2012 Apr; 122(4):1262-70. PubMed ID: 22426206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of low density lipoprotein receptor (LDLR) transcription by oncostatin M is mediated by the extracellular signal-regulated kinase signaling pathway and the repeat 3 element of the LDLR promoter.
    Li C; Kraemer FB; Ahlborn TE; Liu J
    J Biol Chem; 1999 Mar; 274(10):6747-53. PubMed ID: 10037774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phaleria macrocarpa (Scheff.) Boerl fruit aqueous extract enhances LDL receptor and PCSK9 expression in vivo and in vitro.
    Chong SC; Dollah MA; Chong PP; Maha A
    J Ethnopharmacol; 2011 Sep; 137(1):817-27. PubMed ID: 21763412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.